Literature DB >> 10580965

Non-small cell lung cancer: prognostic factors in patients treated with surgery and postoperative radiation therapy.

J H Lee1, M Machtay, L R Kaiser, J S Friedberg, S M Hahn, M G McKenna, W G McKenna.   

Abstract

PURPOSE: To determine survival outcomes, to identify adverse prognostic factors for relapse, and to compare American Joint Commission on Cancer (AJCC) staging systems in patients with non-small cell lung cancer (NSCLC) treated with surgery and postoperative radiation therapy.
MATERIALS AND METHODS: Between 1980 and 1995, 211 patients with NSCLC underwent surgery and postoperative radiation therapy. Surgery consisted of wedge resection (12.5%), lobectomy (67.8%), or pneumonectomy (19.7%). Pathologic stages (1992 AJCC) included I (n = 22), II (n = 70), IIIA (n = 104), and IIIB (n = 12). Indications for radiation therapy included compromised margins (n = 81) and/or positive mediastinal nodes (n = 55). Prognostic factors were identified by using univariate and multivariate models.
RESULTS: Overall 3-year survival for patients with stage I, II, and IIIA cancer was 58.9%, 44.1%, and 43.2%, respectively. Older age (P = .008), male sex (P = .021), large primary tumor (P = .004), and multiple positive mediastinal nodes (P = .046) were associated with worse rates of survival. Actuarial risk of local-regional relapse (36 patients) was 21.4% at 3 years. In a multivariate model, use of wedge resection (P = .001), positive margins (P = .010), and larger pathologic tumor (P = .059) were risk factors for local-regional recurrence. Actuarial rate of distant failure was 55.2% at 3 years.
CONCLUSION: Local-regional control can be achieved with surgery and radiation therapy in approximately 80% of patients; however, the rate of distant metastasis remains unacceptably high. Other variables, such as multiple positive nodes, may serve to identify patients at higher risk for relapse and poorer survival. Methods for improving treatment outcomes in these patients should be pursued.

Entities:  

Mesh:

Year:  1999        PMID: 10580965     DOI: 10.1148/radiology.213.3.r99dc23845

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  7 in total

Review 1.  Advances in adjuvant systemic therapy for non-small-cell lung cancer.

Authors:  David Leong; Rajat Rai; Brandon Nguyen; Andrew Lee; Desmond Yip
Journal:  World J Clin Oncol       Date:  2014-10-10

Review 2.  Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy.

Authors:  Jeffrey M Craft; Dennis Hallahan
Journal:  Future Med Chem       Date:  2011-05       Impact factor: 3.808

3.  Cytosolic phospholipase A2: targeting cancer through the tumor vasculature.

Authors:  Amanda Linkous; Ling Geng; Andrej Lyshchik; Dennis E Hallahan; Eugenia M Yazlovitskaya
Journal:  Clin Cancer Res       Date:  2009-02-24       Impact factor: 12.531

4.  Cytosolic phospholipase A2 and lysophospholipids in tumor angiogenesis.

Authors:  Amanda G Linkous; Eugenia M Yazlovitskaya; Dennis E Hallahan
Journal:  J Natl Cancer Inst       Date:  2010-08-20       Impact factor: 13.506

5.  Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: A single-center, retrospective study.

Authors:  Wei Wei; Jiao Zhou; Qun Zhang; De-Hua Liao; Qiao-Dan Liu; Bei-Long Zhong; Zi-Bin Liang; Yong-Chang Zhang; Rong Jiang; Gui-Yun Liu; Chen-Yang Xu; Huai- Li Zhou; Su-Yu Zhu; Nong Yang; Wen Jiang; Zhi-Gang Liu
Journal:  Cancer Med       Date:  2020-02-26       Impact factor: 4.452

6.  Postoperative radiation therapy for non-small cell lung cancer and thymic malignancies.

Authors:  Daniel R Gomez; Ritsuko Komaki
Journal:  Cancers (Basel)       Date:  2012-03-14       Impact factor: 6.639

7.  Cytosolic phospholipaseA2 inhibition with PLA-695 radiosensitizes tumors in lung cancer animal models.

Authors:  Dinesh Thotala; Jeffrey M Craft; Daniel J Ferraro; Rama P Kotipatruni; Sandeep R Bhave; Jerry J Jaboin; Dennis E Hallahan
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.